After Novo’s Alzheimer’s Setback, Neurophet Bets Imaging AI Shows When Drugs Really Works

Neurophet went into last year’s meeting of the Radiological Society of North America (RSNA) betting that the Alzheimer’s story around GLP-1 drugs could break either way. What its co-CEO Kim Dong-hyeon was sure of, though, was that the next generation of dementia trials would rise or fall on how precisely they used imaging and biomarkers. “Drug developers love a clean biomarker plot,” says Kim. “But if imaging and fluid markers are not built into the trial from day one, in a way that actually defines who should be in the study, you end up proving a mechanism and failing a trial.”